Panbela Therapeutics, Inc. · OTC:PBLA

Panbela Therapeutics — Investor Presentation (March 2022)

21 slides from Panbela Therapeutics's investor presentation, Mar 21, 2022

  1. Slide 1: Company Overview

    Company Overview March 2022 Last modified on 3/21/22

  2. Slide 2: Cautionary Statements

    Cautionary Statements Certain statements in this presentation are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are provided under the protection of the safe harbor for forward-looking statements provided by that Act. Forward-looking statem

  3. Slide 3: Company Highlights

    Company Highlights New Therapeutic Class For Solid Tumors ― Developing small molecule polyamine metabolic inhibitors with tumor and organ-specific preferential uptake ― Multiple cancer types with known elevated polyamine levels represent potential targets ― Novel Trojan Horse polyamine metabolic inh

  4. Slide 4: Panbela Leadership Team and Board of Directors

    Panbela Leadership Team and Board of Directors  Collectively developed 10 FDA-approved therapies generating billions in sales Leadership Team Board of Directors Jennifer K. Simpson, PhD, MSN, CRNP Michael T. Cullen, MD, MBA, ABIM President & CEO Jennifer K. Simpson, PhD, MSN, CRNP Susan Horvath, CP

  5. Slide 5: Pancreatic Cancer: a Major Unmet Medical Need

    Pancreatic Cancer: a Major Unmet Medical Need  Globally, the number of deaths caused by, and incidence of, pancreatic cancer has more than doubled from 1990 to 2017 5-Year Survival Rate (U.S.) Deaths in the U.S. (Thousands) 100% 98% 160 90% Lowest survival rate 3rd leading cause 136 among major can

  6. Slide 6: Objective Response Rate Comparison Among Prior PDAC Trials

    Objective Response Rate Comparison Among Prior PDAC Trials  In addition to strong ORR results, 70% of SBP-101 patients presented CA 19-9 biomarker reductions of greater than 60% MPACT Registration Trial Halozyme Cohort 4 + P1b Interim P3 P3 Ongoing Approved and SOC Discontinued 60% 70% 70% 48% +25p

  7. Slide 7: Increased Polyamine Levels Can Enhance the Malignant Potential of Cancer Cells

    Increased Polyamine Levels Can Enhance the Malignant Potential of Cancer Cells and May Decrease Anti-Tumor Immunity  Many tumors maintain greatly elevated levels of polyamines to support their rapid growth and survival ‒ Of all human tissues, the pancreas has the highest level of native spermidine

  8. Slide 8: SBP-101 MOA (Trojan Horse): Synthetic Polyamine Analogue

    SBP-101 MOA (Trojan Horse): Synthetic Polyamine Analogue  SBP-101 is a synthetic analogue of spermine being designed to exploit the self-regulating nature of polyamine metabolism  SBP-101 preferentially accumulates in tumor cells and downregulates the polyamine metabolic pathway, lowering producti

  9. Slide 9: SBP-101 Phase 1 PDA Study Design

    SBP-101 Phase 1 PDA Study Design* Overview Design  Open-label P1A/1B study to assess safety, tolerability and PK Dose Enrolled Dosing Schedule when combined with Nab-Paclitaxel and Gemcitabine Cohort 1 (n = 4) 0.2 mg/kg only  Identify P2 dose and schedule and assess preliminary efficacy of 3-drug

  10. Slide 10: Clinical Importance of CA 19-9 Biomarker

    Clinical Importance of CA 19-9 Biomarker  Carbohydrate antigen (CA) 19-9 is a type of antigen found in the blood that is often elevated in pancreatic disease  Studies have suggested that decreases in CA 19-9 levels are correlated with improved prognosis; ≥60-75% declines in CA 19-9 levels correlat

  11. Slide 11: CA 19-9 Biomarker and Survival Benefit Correlation

    CA 19-9 Biomarker and Survival Benefit Correlation  Patients in the MPACT study (Phase III Gem+Nab) whose CA 19-9 levels decreased saw an approximate 5-month incremental median survival benefit (P=.001) compared to patients with unchanged or increased CA 19-9 levels  Greatest survival benefit obse

  12. Slide 12: Interim Cohort 4 + P1B CA 19-9 Positive Biomarker Data

    Interim Cohort 4 + P1B CA 19-9 Positive Biomarker Data  70% of subjects had a maximum CA 19-9 decrease greater than 60%  90% of subjects had a decrease in CA 19-9 levels CA 19-9 tumor marker often released by pancreatic cancer cells BEST CA 19-9 Change from Baseline by RECIST Response Percent Chan

  13. Slide 13: Preliminary Efficacy of SBP-101 + Gemcitabine/Nab-paclitaxel in First-Line Metastatic PDA

    Preliminary Efficacy of SBP-101 + Gemcitabine/Nab-paclitaxel in First-Line Metastatic Pancreatic Ductal Adenocarcinoma BEST OVERALL RESPONSE Overall Disease CR PR SD PD Response Control SBP-101 (0.40 mg/kg) + G/A* (Ph1a COHORT 2) 0 5 (71%) 2 (29%) 0 5/7 (71%) 5/7 (71%) n=7 SBP-101 (0.40 mg/kg) + G/A

  14. Slide 14: SBP-101 + Gemcitabine/Nab-paclitaxel Overall Survival

    SBP-101 + Gemcitabine/Nab-paclitaxel Overall Survival* Cohort 2 N=7: 2 patients with long term survival. • One still alive at 33.1 months • One deceased at 30.3 months Cohort 4+1b = 6 patients still alive Data as of 07MAR2022 - post ASCO GI Poster Presentation, January, 2022 * Maturing data – Not Ye

  15. Slide 15: Safety Results

    SBP-101 + Gemcitabine/Nab-paclitaxel Demonstrated a Similar Safety Profile to Gemcitabine/Nab-paclitaxel in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Safety Results SBP- Grade ≥3 adverse events attributable to any study medication, N=50. Grade ≥3 AEs of Special Interest N G+A %** 101% H

  16. Slide 16: Phase 2/3 Pancreatic Cancer Trial in Previously Untreated Metastatic PDAC

    Phase 2/3 Pancreatic Cancer Trial in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma A Randomized, Double-Blind, Placebo Controlled Study of Nab-Paclitaxel and Gemcitabine with or Without SBP-101 Panbela Therapeutics 16

  17. Slide 17: Area of Future Exploration: SBP-101 Combined with IOs

    Area of Future Exploration: SBP-101 Combined with IOs  Historical clinical trials using IO agents have been unsuccessful  A potential hypothesis is that excess polyamines, especially spermine, insulate the tumor microenvironment from immune cells  SBP-101 is a synthetic analogue of spermine, whic

  18. Slide 18: Significant SBP-101 Polyamine Metabolic Inhibitor Pipeline Expansion Opportunity

    Significant SBP-101 Polyamine Metabolic Inhibitor Pipeline Expansion Opportunity Upregulated polyamine metabolism is also a phenotypic change caused by certain oncogenic mutations, creating potential for future patient stratification strategies in other cancers Discovery Preclinical IND Ready Phase

  19. Slide 19: Cash Balance and Capitalization

    Cash Balance and Capitalization Cash Balance as of September 30, 2021 $14,072,000 Capitalization Table Common Stock Outstanding as of September 30, 2021 13,434,152 Stock Options @ $5.87 WAEP 2,489,136 Restricted Stock Units Outstanding 16,185 Warrants @ $4.59 WAEP 5,109,501 Common stock outstanding

  20. Slide 20: Milestones

    Milestones 2022 ► ASCO GI Poster Presentation (1Q – January) ► First Patient Enrolled in randomized phase 2 study (1Q’22) ► Final Data from phase 1 trial (1H'22) ► Initiate Ovarian Cancer Clinical Program (1H’22) ► Close Merger Transaction (1H’22) ► Initiate Neoadjuvant Pancreatic Trial (2H'22) Panb

  21. Slide 21: SBP-101 Summary

    SBP-101 Summary Unique dual-attack MOA is synergistic with other agents, potentially enhancing anti-tumor response Favorable safety & tolerability profile and subcutaneous administration in clinical studies to date supports potential ease of use Interim data from Phase 1a/1b trial presented at ASCO

Panbela Therapeutics — Investor Presentation (March 2022) on 6ix